Cart
sales@molnova.com
Elarofiban TFA
CAS No. 198958-89-3
Elarofiban TFA( —— )
Catalog No. M34234 CAS No. 198958-89-3
Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 321 | In Stock |
|
| 10MG | 459 | In Stock |
|
| 25MG | 718 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameElarofiban TFA
-
NoteResearch use only, not for human use.
-
Brief DescriptionElarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.
-
DescriptionElarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number198958-89-3
-
Formula Weight644.56
-
Molecular FormulaC26H34F6N4O8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC(C(F)(F)F)=O.O=C([C@H]1CN(CCC1)C(CCC2CCNCC2)=O)N[C@H](C3=CN=CC=C3)CC(O)=O.OC(C(F)(F)F)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Natalizumab
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
-
Tadocizumab
Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
-
BMS-688521
BMS-688521 BMS-688521 is an orally active and potent inhibitor of LFA-1/ICAM interaction, a small molecule antagonist of leukocyte function-associated antigen-1 (LFA-1), with potential anti-inflammatory activity.
